Following up on our earlier post on NeoVista obtaining continuing funding for their research and clinical trials, I would like to inform readers of my writeups on this company and its clinical trials.

I began following NeoVista in February 2007, writing an initial piece describing the procedure and initial clinical results. I also asked a series of questions of management and printed their responses. This first piece was:

NeoVista Epi-Retinal Strontium 90 Treatment for Wet AMD

and the link to the article is:

http://irvaronsjournal.blogspot.com/2007/02/neovista-epi-retinal-strontium-90.html ^[1]

In July 2007, the company announced the initiation of the CABERNET clinical study, and I posted an update, including more questions about the study to management. This piece was:

NeoVista Epi-Retinal Strontium 90 Treatment for AMD Update

and that link is:

http://irvaronsjournal.blogspot.com/2007/07/neovista-epi-retinal-strontium-90.html ^[2]

In November 2007, during the annual AAO Meeting, NeoVista provided new data from its one-year feasibility study, and I published the data in a second update:

NeoVista Epi-Retinal Strontium 90 Treatment for AMD: Update 2

That link is:

http://irvaronsjournal.blogspot.com/2007/11/neovista-epi-retinal-strontium-90.html ^[3]

And, the final update (at least to date) was written following the 2008 Retina Society Meeting in September 2008. This included 18-month data from the Phase II feasibility study, and concluded with the statement: “With the continued promise of these Phase II trial results, NeoVista continues to enroll patients in the company’s pivotal trial, CABERNET. CABERNET is a multicenter, randomized, controlled study that will enroll 450 subjects at 45 sites worldwide, evaluating the safety and efficacy of NeoVista’s epiretinal brachytherapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis (ranibizumab) versus Lucentis alone.”

NeoVista Epi-Retinal Strontium 90 Treatment for AMD: Update 3

The link to this posting is:

http://irvaronsjournal.blogspot.com/2008/10/neovista-epi-retinal-strontium-90.html ^[4]

I hope these postings tell you everything you might want to know about this important step in possibly reducing the number of intravitreal injections in alleviating/stopping wet AMD.